Redefining what’s possible in cystic fibrosis treatment
Our vision is to fully normalize CFTR function
Pipeline
We’re developing novel small molecule therapies targeting the most common genetic mutation affecting cystic fibrosis (CF) patients, ΔF508, with the goal of normalizing CFTR function.
Discovery
Lead Optimization
DC / IND-Enabling
Phase 1
Mechanism:
Core Values
Excellence together to redefine what is possible for patients
Intentional Innovation
Unwavering Integrity
Continuous Collaboration
Flexible First
Active Trust
Every day I get to go to work and interact with an awesome group of people. Even cooler than that, we all do work that will positively impact patients’ lives!
Direct…but from every conceivable angle! That’s how I would describe the drug discovery strategy at Sionna. I am grateful for the opportunity to work toward the goal of normal CFTR function for CF patients.